BioBeats – Entering a Higher Octave

研报英文原文证据摘录

BioBeats – Entering a Higher Octave

June 18, 2026

Total return is defined as the sum of (1) the percentage difference between the target price and the current price and (2) the expected dividend yield of

the stock.

Other Disclosures

Foreign Analyst Disclosure: To the extent this Research Report has been prepared on a non-US security and the Research Analysts identified are employed

by affiliates outside the US such as Cantor Fitzgerald Europe (“CFE”) the Research analysts employed outside the US by affiliates of Cantor Fitzgerald &

Co. are not Associated Persons of CF&Co. and are not registered as Research Analysts with the Financial Industry Regulatory Authority (“FINRA”) and

therefore may not be subject to FINRA Rule 2241 restrictions on communications with a subject company, public appearances and trading securities held

by a research analyst’s account. Please refer to cover page and the final page of the research report for information identifying the identity of the Research

Analysts and the affiliates involved in publishing this Research Report.

This report is for informational purposes only and is based on publicly available data believed to be reliable, but no representation is made that such data

are accurate or complete. Opinions and projections contained herein reflect our opinion as of the date of this report and are subject to change. Pursuant

to Cantor Fitzgerald's policy, the author of this report does not own shares in any company he/she covers.

Cantor Fitzgerald and the Cantor Fitzgerald logo are trademarks or registered trademarks of Cantor Fitzgerald Securities or its affiliates in the U.S. and

other countries. Other trademarks appearing herein are the property of their respective owners. Neither Cantor Fitzgerald Securities nor its affiliates are